Cargando…

Standardization of the [(68)Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer

Prostate-specific membrane antigen (PSMA) is a glycoprotein present in the prostate, that is overexpressed in prostate cancer (PCa). Recently, PSMA-directed radiopharmaceuticals have been developed, allowing the pinpointing of tumors with the Positron Emission Tomography (PET) or Single Photon Emiss...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuscaldi, Leonardo L., Sobral, Danielle V., Durante, Ana Claudia R., Mendonça, Fernanda F., Miranda, Ana Cláudia C., da Cunha, Marcelo L., Malavolta, Luciana, Mejia, Jorge, de Barboza, Marycel F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142994/ https://www.ncbi.nlm.nih.gov/pubmed/33918987 http://dx.doi.org/10.3390/ph14050385

Ejemplares similares

Comparative Study of Two Oxidizing Agents, Chloramine T and Iodo-Gen(®), for the Radiolabeling of β-CIT with Iodine-131: Relevance for Parkinson’s Disease
por: R. Durante, Ana Claudia, et al.
Publicado: (2019)

Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
por: Ringheim, Anna, et al.
Publicado: (2020)

Radiochemical and biological assessments of a PSMA-I&S cold kit for fast and inexpensive (99m)Tc-labeling for SPECT imaging and radioguided surgery in prostate cancer
por: Fuscaldi, Leonardo Lima, et al.
Publicado: (2023)

Comparative Evaluation of Radiochemical and Biological Properties of (131)I- and [(99m)Tc]Tc(CO)(3)-Labeled RGD Analogues Planned to Interact with the α(v)β(3) Integrin Expressed in Glioblastoma
por: Sobral, Danielle V., et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA and [(68)Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration
por: Ghezzo, Samuele, et al.
Publicado: (2023)

Evaluation of (68)Ga-Radiolabeled Peptides for HER2 PET Imaging
por: Ducharme, Maxwell, et al.
Publicado: (2022)

A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer
por: Wang, Guochang, et al.
Publicado: (2023)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

In vitro and in vivo comparative study of a novel (68)Ga-labeled PSMA-targeted inhibitor and (68)Ga-PSMA-11
por: Chen, Huanyu, et al.
Publicado: (2021)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Biodistribution of (68/67)Ga-Radiolabeled Sphingolipid Nanoemulsions by PET and SPECT Imaging
por: Díez-Villares, Sandra, et al.
Publicado: (2021)

Investigation of the halo-artifact in (68)Ga-PSMA-11-PET/MRI
por: Heußer, Thorsten, et al.
Publicado: (2017)

(68)Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
por: de Keizer, Bart, et al.
Publicado: (2016)

Fully automatic prognostic biomarker extraction from metastatic prostate lesion segmentations in whole-body [(68)Ga]Ga-PSMA-11 PET/CT images
por: Kendrick, Jake, et al.
Publicado: (2022)

Preparation, Characterization, and Radiolabeling of [(68)Ga]Ga-NODAGA-Pamidronic Acid: A Potential PET Bone Imaging Agent
por: Ashhar, Zarif, et al.
Publicado: (2020)

Fully automated radiolabeling of [(68)Ga]Ga-EMP100 targeting c-MET for PET-CT clinical imaging
por: Rusu, Timofei, et al.
Publicado: (2023)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [(68)Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
por: Rosar, Florian, et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

What to Trust, PSA or [(68)Ga]Ga-PSMA-11: Learn from Experience
por: Viglialoro, Rita, et al.
Publicado: (2021)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
por: Mapelli, Paola, et al.
Publicado: (2022)

External validation of a convolutional neural network for the automatic segmentation of intraprostatic tumor lesions on (68)Ga-PSMA PET images
por: Ghezzo, Samuele, et al.
Publicado: (2023)

Cost-effectiveness of the implementation of [(68)Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging
por: van der Sar, Esmée C. A., et al.
Publicado: (2022)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
por: Sathekge, Mike, et al.
Publicado: (2016)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Letter to the Editor: (68)Ga-PSMA-11 for renal cortical PET imaging
por: Sarikaya, Ismet
Publicado: (2022)

Could (68)Ga-DOTA-UBI-29-41 Help Identify Chronic Osteomyelitis on PET/CT Images? A Pilot Study
por: Nogueira, Solange Amorim, et al.
Publicado: (2023)

Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
por: Lawhn-Heath, Courtney, et al.
Publicado: (2020)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

Development of a Single Vial Kit Solution for Radiolabeling of (68)Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients
por: Ebenhan, Thomas, et al.
Publicado: (2015)

Site-Specific (68)Ga Radiolabeling of Trastuzumab Fab via Methionine for ImmunoPET Imaging
por: Yue, Thomas T. C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8a4su9unrl8guivfbpl83utt13